Proton-Pump Inhibitors and Fragility Fractures in Vulnerable Older Patients

This is the author accepted manuscript. Available from Nature Publishing Group via the DOI in this record.To the Editor: Proton Pump Inhibitors (PPIs) taken for ≥1 year have been linked to increased fragility fracture (FF) risk, prompting the US FDA to issue a related warning. The oldest old (≥85) and patients with comorbidities may be at greater risk (1); however, little or no evidence has been available in these groups of vulnerable people. In this retrospective-matched cohort study with difference-in-difference methods, we investigated the 4-year FF risk in older patients (≥60) and patients with comorbidities. [...]This research is funded by the National Institute for Health Research (NIHR), grant number: PB-PG-0214-3309. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the UK Department of Health